Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Erez's HEM TEST notes 2024 > BMT facts > Flashcards

BMT facts Flashcards

1
Q

Timing of FLT3i/IDHi maintenance after allo transplant

A

+30
less evidence for IDHi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Duration of FLT3i maintenance after allo transplant

A

6-24 months
depending on tolerability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Tx of ICANS

A

for G>1
IV dexamthasone 10 mg q6h
if severe IV solumedrol + anakinra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Tumor inflammation–associated neurotoxicity

A

Pseudoprogression in the CNS after CAR-T
Different entity than ICANS
Focal inflammation at the tumor site, not general like ICANS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Thiamine Tx after CAR-T

A

For severe CRS / ICANS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Rare neurologic complications after CAR-T

A

Myelitis
May be relate to PD1 Tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Median time to ICANS

A

5-6 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Movement and neurocognitive treatment–emergent adverse
events (MTNs) in relation to CAR-T

A

1-3 months after BCMA CAR-T
Parkinsonism
Risk factors are CRS, ICANS and CAR-T persistence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Axi-cell costimulatory domian

A

CD28

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DLI CR in AML

A

30-40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DLI CR in ALL

A

15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Acute and chronic GVHD rates after DLI

A

Acute 12%
Chronic 30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Timing of prophylactic DLI

A

3-6 months after transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Strategies of DLI

A

Prophylactic- for HR pts
Preemptive- in MRD relapse or loss of donor chimerism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Dosing schedule of DLI

A

Once a month for 4-12 months
Until MRD negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IVIG after CAR-T

A

IgG< 400
or rec. infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Umbilical cord vs peripheral blood stem cells

A

Umbilical- less GVHD, longer engraftment
PB- higher GVL, higher GVHD, faster engraftment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

MAC protocols

A

Cy120/TBI 12Gy
Cy120/Bu 16
F/ Bu 16

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

RIC agents

A

TLI
ATG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Buslfan SE

A

VOD
Seizures
Pulmonary fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

1s line Tx of chronic GVHD

A

Steorids
CNI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

2nd line Tx of chronic GVHD

A

Ruxo
Ibrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

3rd line Tx of chronic GVHD

A

Belumosidil
ROCK2 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

CMV prophylaxis post tranplant

A

Letermovir (Prevymis) for CMV positive pts
Especially in pts with CMV negative donor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Important SE of CNI
TMA PRES Nephro Hyperkalemia
26
Anakinra in CRS/ICANS
Effective in both Used for refractory symptoms
27
2nd line Tx of acute GVHD
Ruxo
28
Salvage as bridging to ASCT or sequential
ASAP trial No advantage for salvage Limitation- pts in ASCT arm got aggressive conditioning So results are not very informative
29
Lab risk factors for high grade CRS
LDH Ferritin CRP PLT
30
ICAHT
Immune effector cell associated hematoxicity Long term cytopenias after CAR-T
31
IEC-HC
HLH after CAR-T treat with tocilizumab or roxulitinb
32
Stem cell marker for collection before ASCT
CD34
33
Preference of BM graft in aplastic anemia
BM Less GVHD
34
Preferred amount of CD34 cells for auto
Min 2 10^6 Preffered 4-5 10^6
35
Preferred amount of CD34 for allo
5-6 10^6
36
Prelixafor
Mosobil CXCR4 For poor mobilizers of stem cells for collection before auto/allo If CD34 in PB is less than 10 to microilter
37
Drugs lowering the yield of SC collection
Lenalidomide Fludarabine
38
DLI SE
GVHD Aplasia
39
ECP
Add psoralen Irradiation of lympocytes Used in: Sezary Scleroderma GVHD- less used now bcs of ruxo May be effective as combination ECP + ruxo for skin GVHD
40
BCNU SE
Lung toxicity
41
Relevant HLA in transplant
Class I- HLA A B C Class II- HLA DR DQ
42
F to M allo tranplant
More GVHD Due to attack of Y chromosome
43
Reactivation of CMV risk after allo
CMV positive pts with CMV negative donors Prevent with letermovir in CMV positive pts
44
Consequence of ABO missmatch in allo transplant
Major- Ab in pts against donor antigen. Late engrafment. PRCA. Prevent with RBC depleted transplant. Minor- ab in donor against pt antigen. Hemolysis. Prevent with plasma depletion. Bidirectional- both. eg A and B ABO missmatch is related to worse OS with increased TRM
45
Haplo vs MUD depending on conditioning
RIC may be less effective in Haplo but controversial
46
Haplo SE
CRS Slower engraftment
47
TBI risks/benefits
GVHD Better in sanctuary sites (ALL)
48
Bu/CY vs Bu/Flu
Bu/Flu less toxic than Bu/Cy Less NRM Flu preffered when age > 40
49
Diseases with benefit of RIC
CML CLL FL MCL Due to high GVT in these diseases
50
When to add ATG for GVHD prophylaxis
MUD
51
MSD MAC tranplant GVHD prophylaxis
CNI+MTX Add ATG for MUD
52
MSD RIC tranpalnt GVHD prophylaxis
CNI+ MMF Add ATG for MUD
53
aGVHD G2 Tx
Solumderol For at least 1 week Then start slow tapering Add budesonide for GI GVHD
54
Screening for chronic GVHD
Genitalia PFTs
55
Tx of pulmonary chronic GVHD (BOS)
Fluticasone Azenil Monteleukast
56
Dose of prednisone in GVHD
2 mg/kg in acute 1 mg/kg in chronic
57
Belmusodil and axatilimab as 3rd line chronic GVHD
Effective in reducing fibrosis ROCKstar phase II
58
Axatilimab in CGVHD
Anti-CSF1R Phase 2 study showing efficacy
59
GVHD with PTCY
Less GVHD in haplo and also in matched donors related/unrelated
60
Risk factors for prolonged cytopenias after CAR-T
CRS severity Prior BMT Pre CAR-T cytopenias
61
Letermovir dose adjustment
Reduce from 480 mg to 240 mg if taking CsA
62
Which CAR-T is not approved for PMBCL
Tisa-cell
63
Bridging Tx in CAR-T studies of DLBCL
Not in axi Allowed in tisa/liso
64
Phase of CAR-T studies in 3rd line DLBCL
Phase II
65
Phase of CAR-T studies in 2nd line DLBCL
Phase III
66
Axi cell 2nd line benefit
OS!!
67
Conditiong in AML in young pts < 40
BU/Cy
68
Conditiong in AML in young pts 40-65
BU/Flu
69
Conditiong in AML in young pts >65
RIC

Erez's HEM TEST notes 2024 (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions